Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%.

Revenue of $558 million in the first quarter increased 27% year over year compared to Q1 2025. We are raising the midpoint of our full-year 2026 revenue guidance by 2% to reflect better-than-expected demand in the first quarter.

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 ...

Enables Solid-State Battery Production at Existing Li-Ion Facilities Without New EquipmentDAYTON, Ohio, April 21, 2026 /PRNewswire/ -- Solidion Technology Inc. (Nasdaq: STI), today announced the grant of a series of key patents covering its proprietary liquid-to-solid electrolyte conversion platform — a technology that enables existing lithium-ion battery manufacturers to produce solid-state batteries without new equipment or process investment — adding to the Company's portfolio of over 345 patents.